ADCs in Lung Cancer: Three Approved, Two More Coming, and a Toxicity Framework Every Oncologist Needs
Introduction: Over 150 Trials, Three Approvals, and a Field Moving Fast
The antibody-drug conjugate landscape in lung cancer has expanded from a promising concept to a clinically transformative drug class within the span of a few years. There are currently over 150 clinical trials of ADCs globally in lung cancer, targeting multiple surface antigens with a variety of payloads and linker technologies. Three ADCs are now FDA-approved for non-small cell lung cancer indications. Two more are poised for approval in small cell lung cancer. Understanding which drug applies to which patient, and how to manage the toxicities that are common to this class, has become a core clinical skill.
How ADCs Work: Selective Killing and the Bystander Effect
ADCs deliver cytotoxic payloads selectively to tumor cells through a targeting antibody that binds a surface antigen. After binding, the ADC is internalized, the linker is cleaved, and the payload kills the cell from within. This selective delivery reduces systemic toxicity compared to conventional chemotherapy.
The bystander effect adds an additional dimension: when the linker is cleaved extracellularly, the freed payload can diffuse into neighboring cells and kill them even if they do not express the target antigen. This bystander killing can be deliberately engineered or an incidental feature of the linker chemistry. It extends the anti-tumor effect beyond antigen-positive cells and may partially explain why ADCs can work in tumors with heterogeneous target expression.
HER2 in NSCLC: Mutation Versus Overexpression Are Two Separate Indications
HER2 in non-small cell lung cancer exists in three distinct forms that carry different clinical implications: kinase domain mutations (exon 20 insertions and others), IHC overexpression (scored as 1+, 2+, or 3+), and amplification. The TDXd (trastuzumab deruxtecan) approvals address the first two, but separately.
HER2 mutation: DESTINY-Lung01 at the higher 6.4 mg/kg dose showed approximately 55% ORR in the HER2 mutant cohort, but pneumonitis occurred in approximately 26% of patients. DESTINY-Lung02 evaluated the lower 5.4 mg/kg dose: similar ORR in the high 50s, but ILD rate reduced to approximately 12.9% versus approximately 28% at the higher dose. TDXd was FDA-approved in August 2022 for HER2-mutated NSCLC after one prior systemic therapy. Of note: for HER2-mutated NSCLC, a HER2 TKI (zongertinib or zartinib) is actually the preferred frontline approach given the high response rates; TDXd comes into play after TKI failure.
HER2 IHC 3+ (tumor-agnostic): DESTINY-PanTumor02 and related basket trial data showed ORRs of 44 to 80% across solid tumors with IHC 3+ expression, including approximately 44% in lung cancer specifically. Because of this, TDXd received a tumor-agnostic FDA approval in August 2024 for HER2 IHC 3+ tumors after one prior systemic therapy.
Critical clarification: HER2 IHC 2+ is NOT approved. The approval is specifically for 3+ expression. Trastuzumab and pertuzumab have minimal efficacy in HER2-mutated or low-overexpression NSCLC and are not appropriate choices.
cMET Overexpression: Telisotuzumab Vedotin and the Importance of the Threshold
Telisotuzumab vedotin (teliso-V) targets cMET overexpression, which is distinct from MET exon 14 skipping mutations. The LUMINOSITY trial evaluated teliso-V in patients with cMET overexpression by IHC, stratified into two cohorts:
The C5 cohort (IHC 3+ in at least 50% of cells) showed approximately 35% ORR. The C3 intermediate cohort (IHC 3+ in 25 to 50% of cells) showed approximately 24% ORR. Median PFS was approximately 5.5 to 6 months and OS approximately 14 months across both cohorts.
FDA approval came in May 2025 for high cMET expression (≥50% of cells with IHC 3+) in non-squamous NSCLC after one prior systemic therapy. The intermediate C3 group is not approved.
The practical implication: when a post-progression biopsy shows cMET IHC 3+ staining, the percentage of positive cells matters. If fewer than 50% of cells are 3+, the patient does not meet the approved indication. Insurance coverage will likely follow the approved threshold. The intermediate group data are reasonable compared to docetaxel historical benchmarks, making it worth pursuing off-label if no other options exist, but approval is the anchor.
TROP2: Dato-DXd After EGFR TKI and Platinum
TROP2 is broadly expressed in non-small cell lung cancer and has emerged as an actionable target through datopotamab deruxtecan (Dato-DXd). TROPION-Lung01 compared Dato-DXd to docetaxel across an unselected NSCLC population: PFS improved from 3.7 to 4.4 months, modest overall but with subgroup signals suggesting the benefit is concentrated in non-squamous patients and those with actionable genomic alterations.
TROPION-Lung05 addressed the latter subgroup directly, enrolling patients with actionable genomic alterations (mostly EGFR-mutated) who had progressed on both TKI and platinum chemotherapy. In this population: overall ORR approximately 36%, with the EGFR cohort at approximately 44%; PFS approximately 5.5 months; OS approximately 14 months.
FDA approval for Dato-DXd covers EGFR-mutated NSCLC after prior EGFR TKI and platinum chemotherapy. This slots Dato-DXd into the post-osi/post-platinum sequence, where TDXd is also approved with similar indication overlap. Questions about sequencing these two agents are not yet answered by prospective data.
ADC Toxicity: The Framework Every Prescriber Needs
Three toxicities are central to ADC use in lung cancer: pneumonitis, neuropathy, and (for Dato-DXd specifically) ocular toxicity.
Pneumonitis is the most consequential and potentially lethal toxicity:
- TDXd: approximately 12 to 15% any grade in the breast cancer dose context; similar range in lung cancer
- Teliso-V: approximately 10%
- Dato-DXd: similar range
Grade 1 is asymptomatic and detectable only by CT imaging. The threshold for CT scanning should be low — patients do not typically volunteer symptoms when ILD is early. Stop the drug at grade 1; monitor closely; consider steroids; rechallenge may be possible once resolved. Grade 2 (symptomatic) requires stopping the drug, initiating steroids promptly, and involving pulmonology. The timeline for pneumonitis with TDXd is unpredictable, including cases of delayed onset many months after starting treatment; this requires ongoing vigilance even in patients who have been on treatment for a long time without incident.
Neuropathy occurs in approximately half of patients on ADC regimens. This is largely attributable to the topo-1 payload shared by TDXd and other ADCs in this class. It requires proactive monitoring and dose modification when it reaches functional significance.
Ocular toxicity (Dato-DXd): Dry eyes and keratitis are the distinguishing toxicities of Dato-DXd relative to TDXd and teliso-V. Ophthalmology evaluation before starting Dato-DXd is recommended. Management includes lubricating eye drops and topical steroid-based solutions. Grade 3 ocular toxicity is uncommon but does occur.
SCLC ADCs: Two Promising Compounds Close to Approval
Two ADCs are generating particularly compelling data in small cell lung cancer:
B7H3-targeting ADC (TDXd-class payload): Phase 2 data in 137 patients: 56% ORR in second-line, 45% ORR in third-line and beyond; PFS approximately 5 months; OS approximately 10 months. CNS ORR approximately 46%. ILD occurred in approximately 12.4% of patients with some grade 5 events. The drug received FDA priority review.
ABV-706 (DLL3-targeting ADC): Preliminary data presented at World Lung showing approximately 58% ORR in heavily pretreated patients; median duration of response approximately 6 months. DLL3 is the same target as tarlatamab (the approved bispecific T-cell engager), and this compound raises the possibility of ADC-based DLL3 targeting as an option after tarlatamab failure.
For Patients
Antibody-drug conjugates are a class of targeted therapy that deliver chemotherapy directly to cancer cells by attaching the drug to an antibody that seeks out a specific protein on the cancer cell's surface. Three of these drugs are now FDA-approved for specific types of non-small cell lung cancer based on molecular features of your tumor, including HER2 mutation, HER2 protein overexpression, cMET overexpression, and EGFR mutation. Ask your oncologist whether your tumor has been tested for these targets and whether an ADC might be appropriate for your situation. If you are prescribed one of these drugs, ask specifically about the risk of lung inflammation (pneumonitis) and what symptoms to watch for.
Key Takeaways
- TDXd approved August 2022 for HER2-mutated NSCLC (after one prior therapy); tumor-agnostic approval August 2024 for HER2 IHC 3+ (after one prior therapy); HER2 IHC 2+ is NOT approved; HER2 TKI is preferred for HER2-mutated NSCLC.
- Teliso-V approved May 2025 for cMET high (IHC 3+ in ≥50% of cells) non-squamous NSCLC; intermediate group (25-50%) not approved; ~35% ORR C5 cohort, ~24% C3 cohort.
- Dato-DXd approved for EGFR-mutated NSCLC post-TKI and platinum; ~44% ORR EGFR cohort, overall ~36% ORR; new toxicities: dry eyes/keratitis (ophthalmology eval before starting).
- Pneumonitis is the key ADC toxicity across all three agents (~10-15%); grade 1 = stop and monitor; grade 2 = stop plus steroids plus pulmonology; onset can be delayed months after starting.
- Neuropathy in ~50% of patients; Dato-DXd ocular toxicity is unique to this agent.
- SCLC ADCs: B7H3 ADC (56% ORR second-line, 46% CNS ORR, priority review); DLL3 ADC ABV-706 (58% ORR pretreated, including post-tarlatamab potential).
References
- DESTINY-Lung01 and DESTINY-Lung02. TDXd in HER2-mutated NSCLC. FDA approval August 2022.
- DESTINY-PanTumor02. TDXd in HER2 IHC 3+ solid tumors. FDA tumor-agnostic approval August 2024.
- LUMINOSITY trial. Telisotuzumab vedotin in cMET-overexpressing NSCLC. FDA approval May 2025.
- TROPION-Lung01. Dato-DXd vs docetaxel in previously treated NSCLC. New England Journal of Medicine, 2024.
- TROPION-Lung05. Dato-DXd in actionable genomic alteration NSCLC. FDA approval 2025.
- B7H3-targeting ADC in SCLC. Phase 2 data, FDA priority review 2026.
- ABV-706 DLL3 ADC in SCLC. Preliminary data, World Lung 2025.
- Nguyen K. "ADCs in Lung Cancer." Presented at the 2026 San Francisco Lung Cancer Conference, San Francisco, CA, May 2026.
